CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance

CNS Pharmaceuticals, Inc.

Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.
Initial RSU grant of 9,500 shares; vests 25% at 6 months, 25% at 12 months, balance quarterly.
Severance: 6 months base salary plus prorated bonus and accelerated equity if terminated without cause.
Former CMO Sandra Silberman receives 3 months base salary severance under separation agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.